Health & Pharm General

Sedra Solutions Receives SOC 2 Type 2 Attestation with Zero Exceptions

🕔3/25/2025 1:00:00 PM

Sedra Solutions, a leader in AI-enhanced financial investigations technology, is proud to announce that it has received attestation of its SOC 2 Type 2 compliance with zero exceptions.

Read Full Article

EIN Presswire Welcomes New General Manager to Lead Global Operations

🕔3/25/2025 12:23:59 PM

EIN Presswire, a division of Newsmatics and a leading online news and press release distribution service, is thrilled to announce Petra Megan's promotion to general manager.

Read Full Article

A' Wellness, Health Promotion, and Preventive Care Design Award Announces Comprehensive Prize Package for 2024

🕔3/25/2025 7:36:37 AM

The A' Wellness, Health Promotion, and Preventive Care Design Award, a highly regarded international design competition, has announced its comprehensive prize package for the 2024-2025 award period.

Read Full Article

Newsmatics Engages Student PR Leaders on Media Transparency, Fake News at PRSSA Event

🕔3/24/2025 12:19:31 PM

Public relations students from across the country recently gathered in Charlotte, North Carolina, to boost their leadership skills, discuss ways to improve collaboration, and learn about Newsmatics’ efforts to combat misinformation in today's media world.

Read Full Article

New Website Launch Expands Access to Targeted Digital Marketing Services in Toronto

🕔3/24/2025 12:08:46 PM

SocialEyes Communications has launched a new website designed to connect businesses and professionals with tailored, results-driven online marketing solutions.

Read Full Article

Memphasys Limited (ASX:MEM) Pivotal Clinical Trial Confirms Best-in-Class Performance

🕔3/24/2025 11:04:07 AM

Memphasys Limited (ASX:MEM) (FRA:IG7) is pleased to announce the successful unblinding and data analysis of its pivotal clinical trial for the Felix(TM) System, confirming its best-in-class performance in sperm selection for Assisted Reproductive Technology.

Read Full Article

NEXT Life Sciences Launches Plan A™ Male Contraceptive’s Clinical Trials

🕔3/21/2025 10:10:28 PM

NEXT Life Sciences, the modern reproductive healthcare company pioneering Plan A™, a first-of-its-kind, long-lasting, and on-demand reversible male contraceptive in development, announces the beginning of its clinical trials, the first set of which will begin in Australia on March 24, 2025.

Read Full Article